JP2003507410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003507410A5 JP2003507410A5 JP2001518029A JP2001518029A JP2003507410A5 JP 2003507410 A5 JP2003507410 A5 JP 2003507410A5 JP 2001518029 A JP2001518029 A JP 2001518029A JP 2001518029 A JP2001518029 A JP 2001518029A JP 2003507410 A5 JP2003507410 A5 JP 2003507410A5
- Authority
- JP
- Japan
- Prior art keywords
- particles
- particle
- combination
- therapeutic
- transition temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002245 particle Substances 0.000 description 32
- 150000003904 phospholipids Chemical class 0.000 description 12
- 239000003814 drug Substances 0.000 description 8
- 230000007704 transition Effects 0.000 description 8
- 229940039227 diagnostic agent Drugs 0.000 description 7
- 239000000032 diagnostic agent Substances 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 230000000069 prophylactic effect Effects 0.000 description 7
- 239000003124 biologic agent Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229940088623 biologically active substance Drugs 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- JKKFKPJIXZFSSB-UHFFFAOYSA-N 1,3,5(10)-estratrien-17-one 3-sulfate Natural products OS(=O)(=O)OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 JKKFKPJIXZFSSB-UHFFFAOYSA-N 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 229940057282 albuterol sulfate Drugs 0.000 description 2
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical group OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 2
- -1 fatty acid esters Chemical class 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 description 1
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229940053934 norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15074299P | 1999-08-25 | 1999-08-25 | |
| US60/150,742 | 1999-08-25 | ||
| PCT/US2000/023048 WO2001013891A2 (en) | 1999-08-25 | 2000-08-23 | Modulation of release from dry powder formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003507410A JP2003507410A (ja) | 2003-02-25 |
| JP2003507410A5 true JP2003507410A5 (https=) | 2007-04-19 |
Family
ID=22535816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001518029A Pending JP2003507410A (ja) | 1999-08-25 | 2000-08-23 | 乾燥粉末製剤からの放出調節 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040018243A1 (https=) |
| EP (1) | EP1210067A2 (https=) |
| JP (1) | JP2003507410A (https=) |
| AU (1) | AU763041B2 (https=) |
| CA (1) | CA2382821A1 (https=) |
| WO (1) | WO2001013891A2 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6956021B1 (en) | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
| US6749835B1 (en) | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
| US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
| US20010036481A1 (en) * | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| US7141236B2 (en) | 2000-07-28 | 2006-11-28 | Nektar Therapeutics | Methods and compositions for delivering macromolecules to or via the respiratory tract |
| AU2002255181A1 (en) * | 2001-05-21 | 2002-12-03 | Britannia Pharmaceuticals Limited | Use of phospholipids in the treatment of degenerative lung disease such as copd or cystic fibrosis and to enhance delivery of drugs |
| GB0120123D0 (en) * | 2001-08-17 | 2001-10-10 | Upperton Ltd | Preparation of microparticles |
| AU2002352836B2 (en) | 2001-11-20 | 2005-09-29 | Alkermes, Inc. | Improved particulate compositions for pulmonary delivery |
| JP2005511629A (ja) * | 2001-11-20 | 2005-04-28 | アドバンスト インハレーション リサーチ，インコーポレイテッド | 持続作用生成物送達用組成物 |
| PT1458360E (pt) * | 2001-12-19 | 2011-07-13 | Novartis Ag | Derivados de indole como agonistas do recetor s1p1 |
| AU2003213402A1 (en) * | 2002-03-18 | 2003-09-29 | Yamanouchi Pharmaceutical Co., Ltd. | Powdery medicinal compositions for inhalation and process for producing the same |
| WO2003079885A2 (en) | 2002-03-20 | 2003-10-02 | Advanced Inhalation Research, Inc. | Inhalable sustained therapeutic formulations |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US7425618B2 (en) * | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| EP1569626A1 (en) | 2002-12-13 | 2005-09-07 | Adagit | Pharmaceutical porous particles |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| CN100365039C (zh) * | 2003-01-31 | 2008-01-30 | 日本瑞翁株式会社 | 可聚合组合物、热塑性树脂组合物、交联树脂以及交联树脂复合材料 |
| KR20060015316A (ko) * | 2003-05-28 | 2006-02-16 | 넥타르 테라퓨틱스 | 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법 |
| WO2006002178A1 (en) | 2004-06-18 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Methods of treatment of endobronchial infections |
| WO2006124446A2 (en) * | 2005-05-12 | 2006-11-23 | Nektar Therapeutics | Sustained release microparticles for pulmonary delivery |
| ITMI20051999A1 (it) * | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| EP1952803A1 (en) | 2007-01-23 | 2008-08-06 | KTB-Tumorforschungs GmbH | Solid pharmaceutical dosage form containing hydrogenated phospholipids |
| DE102007019186B4 (de) * | 2007-04-20 | 2011-11-17 | Qiagen Instruments Ag | Pipettiergerät und Verfahren für dem Betrieb des Pipettiergerätes |
| CN101861311A (zh) | 2007-07-21 | 2010-10-13 | 阿尔巴尼分子研究公司 | 5-吡啶酮取代的吲唑 |
| JP2011504505A (ja) | 2007-11-21 | 2011-02-10 | デコード ジェネティクス イーエイチエフ | 肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤 |
| KR101614723B1 (ko) | 2008-01-11 | 2016-04-22 | 알바니 몰레큘라 리써치, 인크. | Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌 |
| WO2010059836A1 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
| KR20150116466A (ko) | 2009-01-26 | 2015-10-15 | 이스라엘 인스티튜트 포 바이올로지컬 리서치 | 이환형 헤테로사이클릭 스피로 화합물 |
| BR112013007304B1 (pt) * | 2010-09-29 | 2021-12-14 | Pulmatrix, Inc. | Pós secos de cátion de metal monovalente para inalação |
| CN107596518B (zh) | 2012-02-29 | 2021-04-23 | 普马特里克斯营业公司 | 可吸入干粉剂 |
| ES2675720T3 (es) | 2013-01-10 | 2018-07-12 | Pulmokine, Inc. | Inhibidores de quinasa no selectivos |
| US9925184B2 (en) * | 2013-10-11 | 2018-03-27 | Pulmokine, Inc. | Spray-dry formulations |
| CN106061487A (zh) * | 2014-02-03 | 2016-10-26 | 里兰斯坦福初级大学理事会 | 用于微粒递送锌原卟啉的制剂 |
| MX392636B (es) | 2014-10-31 | 2025-03-24 | Glaxosmithkline Ip Dev Ltd | Formulacion en polvo. |
| AU2017281931B2 (en) * | 2016-06-24 | 2023-02-02 | Merz Pharmaceuticals, Llc | Surfactant formulations for inhalation |
| CA3041679A1 (en) | 2016-10-27 | 2018-05-03 | Lawrence S. ZISMAN | Combination therapy for treating pulmonary hypertension |
| CA3085944A1 (en) * | 2017-12-21 | 2019-06-27 | Civitas Therapeutics, Inc. | Surfactant formulations for inhalation |
| WO2019126283A1 (en) * | 2017-12-21 | 2019-06-27 | Civitas Therapeutics, Inc. | Surfactant formulations for inhalation |
| CN112135613A (zh) | 2018-03-20 | 2020-12-25 | 西奈山伊坎医学院 | 激酶抑制剂化合物和组合物及使用方法 |
| EP3846792A4 (en) | 2018-09-06 | 2022-10-12 | Innopharmascreen Inc. | METHODS AND COMPOSITIONS FOR TREATING ASTHMA OR PARKINSON'S DISEASE |
| WO2020142485A1 (en) | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2470296A (en) * | 1948-04-30 | 1949-05-17 | Abbott Lab | Inhalator |
| US2992645A (en) * | 1958-05-06 | 1961-07-18 | Benger Lab Ltd | Disperser for powders |
| US3957965A (en) * | 1967-08-08 | 1976-05-18 | Fisons Limited | Sodium chromoglycate inhalation medicament |
| US4173488A (en) * | 1968-12-23 | 1979-11-06 | Champion International Corporation | Oil-in-water emulsions containing hydropholeic starch |
| GB1410588A (en) * | 1971-08-10 | 1975-10-22 | Fisons Ltd | Composition |
| US4069819A (en) * | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| US4089800A (en) * | 1975-04-04 | 1978-05-16 | Ppg Industries, Inc. | Method of preparing microcapsules |
| US4161516A (en) * | 1975-07-25 | 1979-07-17 | Fisons Limited | Composition for treating airway disease |
| US4181542A (en) * | 1976-10-25 | 1980-01-01 | Nippon Gakki Seizo Kabushiki Kaisha | Method of manufacturing junction field effect transistors |
| US4272398A (en) * | 1978-08-17 | 1981-06-09 | The United States Of America As Represented By The Secretary Of Agriculture | Microencapsulation process |
| US4743545A (en) * | 1984-08-09 | 1988-05-10 | Torobin Leonard B | Hollow porous microspheres containing biocatalyst |
| US4391909A (en) * | 1979-03-28 | 1983-07-05 | Damon Corporation | Microcapsules containing viable tissue cells |
| US4352883A (en) * | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
| DE3274065D1 (de) * | 1981-07-08 | 1986-12-11 | Draco Ab | Powder inhalator |
| EP0072046B1 (en) * | 1981-07-24 | 1986-01-15 | FISONS plc | Inhalation drugs, methods for their production and pharmaceutical formulations containing them |
| DE3141641A1 (de) * | 1981-10-16 | 1983-04-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Ultraschall-kontrastmittel und dessen herstellung |
| US4480041A (en) * | 1982-07-09 | 1984-10-30 | Collaborative Research, Inc. | Use of phosphotriester intermediates for preparation of functionalized liposomes |
| US4572203A (en) * | 1983-01-27 | 1986-02-25 | Feinstein Steven B | Contact agents for ultrasonic imaging |
| US4718433A (en) * | 1983-01-27 | 1988-01-12 | Feinstein Steven B | Contrast agents for ultrasonic imaging |
| US4865789A (en) * | 1983-11-14 | 1989-09-12 | Akzo Nv | Method for making porous structures |
| EP0163696B1 (en) * | 1983-11-14 | 1992-11-25 | Columbia Laboratories, Inc. | Use of a bioadhesive |
| US4679555A (en) * | 1984-08-07 | 1987-07-14 | Key Pharmaceuticals, Inc. | Method and apparatus for intrapulmonary delivery of heparin |
| US5340587A (en) * | 1985-05-22 | 1994-08-23 | Liposome Technology, Inc. | Liposome/bronchodilator method & System |
| JPS63500175A (ja) * | 1985-05-22 | 1988-01-21 | リポソ−ム テクノロジ−，インコ−ポレイテツド | リポソ−ム吸入法および吸入システム |
| WO1987003197A1 (en) * | 1985-11-29 | 1987-06-04 | Fisons Plc | Pharmaceutical composition including sodium cromoglycate |
| GB8601100D0 (en) * | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
| US4990291A (en) * | 1986-04-15 | 1991-02-05 | The United States Of America As Represented By The Secretary Of The Navy | Method of making lipid tubules by a cooling process |
| US4741872A (en) * | 1986-05-16 | 1988-05-03 | The University Of Kentucky Research Foundation | Preparation of biodegradable microspheres useful as carriers for macromolecules |
| NZ221411A (en) * | 1986-08-11 | 1989-10-27 | Innovata Biomed Ltd | Pharmaceutical compositions containing microcapsules and a surfactant |
| DE3637926C1 (de) * | 1986-11-05 | 1987-11-26 | Schering Ag | Ultraschall-Manometrieverfahren in einer Fluessigkeit mittels Mikroblaeschen |
| JPS63122620A (ja) * | 1986-11-12 | 1988-05-26 | Sanraku Inc | ポリ乳酸マイクロスフエア及びその製造方法 |
| US4963297A (en) * | 1987-12-22 | 1990-10-16 | The Liposome Company, Inc. | Spontaneous vesticulation of multilamellar liposomes |
| US5204113A (en) * | 1987-04-09 | 1993-04-20 | Fisons Plc | Pharmaceutical compositions containing pentamidine |
| US4861627A (en) * | 1987-05-01 | 1989-08-29 | Massachusetts Institute Of Technology | Preparation of multiwall polymeric microcapsules |
| US4857311A (en) * | 1987-07-31 | 1989-08-15 | Massachusetts Institute Of Technology | Polyanhydrides with improved hydrolytic degradation properties |
| GB8723846D0 (en) * | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
| US4855144A (en) * | 1987-10-23 | 1989-08-08 | Advanced Polymer Systems | Synthetic melanin aggregates |
| JP2670680B2 (ja) * | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
| US5064650A (en) * | 1988-04-19 | 1991-11-12 | Southwest Research Institute | Controlled-release salt sensitive capsule for oral use and adhesive system |
| US4917119A (en) * | 1988-11-30 | 1990-04-17 | R. J. Reynolds Tobacco Company | Drug delivery article |
| US5015483A (en) * | 1989-02-09 | 1991-05-14 | Nabisco Brands, Inc. | Liposome composition for the stabilization of oxidizable substances |
| IT1228459B (it) * | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| DK0471036T4 (da) * | 1989-05-04 | 2004-07-19 | Southern Res Inst | Indkapslingsfremgangsmåde |
| US5176132A (en) * | 1989-05-31 | 1993-01-05 | Fisons Plc | Medicament inhalation device and formulation |
| US5174988A (en) * | 1989-07-27 | 1992-12-29 | Scientific Development & Research, Inc. | Phospholipid delivery system |
| IT1237118B (it) * | 1989-10-27 | 1993-05-18 | Miat Spa | Inalatore multidose per farmaci in polvere. |
| US5707644A (en) * | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5334381A (en) * | 1989-12-22 | 1994-08-02 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
| US5352435A (en) * | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
| US5123414A (en) * | 1989-12-22 | 1992-06-23 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
| SE9002017D0 (sv) * | 1990-06-06 | 1990-06-06 | Kabivitrum Ab | Process for manufacture of matrices |
| US5614216A (en) * | 1990-10-17 | 1997-03-25 | The Liposome Company, Inc. | Synthetic lung surfactant |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| GB9107628D0 (en) * | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
| SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| US5874063A (en) * | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| US5327883A (en) * | 1991-05-20 | 1994-07-12 | Dura Pharmaceuticals, Inc. | Apparatus for aerosolizing powdered medicine and process and using |
| AU659645B2 (en) * | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
| US5409688A (en) * | 1991-09-17 | 1995-04-25 | Sonus Pharmaceuticals, Inc. | Gaseous ultrasound contrast media |
| US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| EP0679088B1 (en) * | 1992-09-29 | 2002-07-10 | Inhale Therapeutic Systems | Pulmonary delivery of active fragments of parathyroid hormone |
| US5698721A (en) * | 1992-12-17 | 1997-12-16 | Megabios Corporation | Catonic amphiphiles |
| US5994314A (en) * | 1993-04-07 | 1999-11-30 | Inhale Therapeutic Systems, Inc. | Compositions and methods for nucleic acid delivery to the lung |
| US5456917A (en) * | 1993-04-12 | 1995-10-10 | Cambridge Scientific, Inc. | Method for making a bioerodible material for the sustained release of a medicament and the material made from the method |
| TW402506B (en) * | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
| GB9313650D0 (en) * | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
| PT721331E (pt) * | 1993-10-01 | 2002-05-31 | Astrazeneca Ab | Processo i |
| US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| EP0750910A4 (en) * | 1994-03-11 | 1997-07-09 | Yoshitomi Pharmaceutical | PREPARATION OF LIPOSOMES |
| MX9605717A (es) * | 1994-05-18 | 1998-05-31 | Inhale Therapeutic Syst | Metodos y composiciones para la formulacion de polvo seco de interferones. |
| GB9413202D0 (en) * | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
| US5885613A (en) * | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| AR002009A1 (es) * | 1994-12-22 | 1998-01-07 | Astra Ab | Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco. |
| US5612053A (en) * | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
| ATE287703T1 (de) * | 1995-04-14 | 2005-02-15 | Nektar Therapeutics | Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit |
| US6019968A (en) * | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US6309671B1 (en) * | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
| US5780014A (en) * | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US6258341B1 (en) * | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| US5654007A (en) * | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| USRE37053E1 (en) * | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US20020052310A1 (en) * | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US6103270A (en) * | 1996-06-07 | 2000-08-15 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| AU5719798A (en) * | 1996-12-31 | 1998-07-31 | Inhale Therapeutic Systems, Inc. | Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
| CA2277801C (en) * | 1997-01-16 | 2002-10-15 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US6433040B1 (en) * | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
| AU756693B2 (en) * | 1997-09-29 | 2003-01-23 | Novartis Ag | Stabilized bioactive preparations and methods of use |
| JP4549529B2 (ja) * | 1998-01-30 | 2010-09-22 | サイオス，インコーポレーテッド | ペプチドまたはタンパク質の制御放出送達 |
| EA003328B1 (ru) * | 1998-04-08 | 2003-04-24 | Эли Лилли Энд Компани | Легочная и назальная доставка ралоксифена |
| WO1999066903A2 (en) * | 1998-06-24 | 1999-12-29 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| CA2341624C (en) * | 1998-08-25 | 2008-12-02 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
-
2000
- 2000-08-23 EP EP00957674A patent/EP1210067A2/en active Pending
- 2000-08-23 JP JP2001518029A patent/JP2003507410A/ja active Pending
- 2000-08-23 CA CA002382821A patent/CA2382821A1/en not_active Abandoned
- 2000-08-23 AU AU69259/00A patent/AU763041B2/en not_active Ceased
- 2000-08-23 WO PCT/US2000/023048 patent/WO2001013891A2/en not_active Ceased
-
2003
- 2003-04-28 US US10/425,193 patent/US20040018243A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003507410A5 (https=) | ||
| TWI228998B (en) | Method and device for delivering an active agent to the lungs | |
| JP4378057B2 (ja) | 流動抵抗調節されたエアロゾル化活性薬剤送達 | |
| TW474823B (en) | Powder formulations containing, as a diluent, D-melezitose (Α-D-melezitose), β-D-glucopyranoside, O-Α-D-glucopyranosyl-1,3-β-D-fructofuranosyl (β-D-melezitose) or isomelezitose | |
| US7048908B2 (en) | Particles for inhalation having sustained release properties | |
| KR100697479B1 (ko) | 많은 치료학적 양의 에어로졸을 효과적으로 전달하는 방법 | |
| TWI290473B (en) | Phospholipid-based powders for drug delivery | |
| US20020141946A1 (en) | Particles for inhalation having rapid release properties | |
| US20030232019A1 (en) | Inhalable formulations for sustained release | |
| JP2004520409A (ja) | 乾燥粉体製剤からの放出の調節 | |
| US20080226730A1 (en) | Particles for inhalation having rapid release properties | |
| US20040062718A1 (en) | Particles for inhalation having sustained release properties | |
| TW200817047A (en) | Drug microparticles | |
| JP2003507410A (ja) | 乾燥粉末製剤からの放出調節 | |
| JP2010524948A (ja) | 球形インスリン微小粒子の肺送達 | |
| JP2002500192A (ja) | ＡｓｐＢ２８−ヒトインシュリンの投与方法 | |
| CZ300758B6 (cs) | Práškovitý prípravek obsahující perforované mikrostruktury | |
| JP2004503482A5 (https=) | ||
| WO1997035562A1 (en) | Polysaccharide microspheres for the pulmonary delivery of drugs | |
| JP2017506252A (ja) | 吸入用の乾燥粉末製剤 | |
| KR20170039255A (ko) | 흡입용 건조 분말 제형 | |
| CN100515392C (zh) | 有效部位药物沉积得到改善的干粉组合物 | |
| AU2002350606B2 (en) | Particles for inhalation having rapid release properties | |
| JP2002284703A (ja) | 粉末製剤 | |
| Litman | Pharmaceutical Technical Background on Drug-Delivery Methods |